期刊文献+

阿托伐他汀对脂多糖刺激下PBMC分泌TNFα-、IL-1β的影响 被引量:1

Effect of atorvastatin on TNF-α and IL-1β in peripheral blood monocytesstimulated by LPS
下载PDF
导出
摘要 目的观察阿托伐他汀对脂多糖(LPS)刺激下外周血单核细胞(PBMC)分泌TNF-α、IL-1β的影响。方法Ficoll密度梯度离心法分离健康人外周血单个核细胞,不同浓度阿托伐他汀预处理2 h,而后加入10 ng/ml LPS共同培养24 h,采用酶联免疫吸附测定法(ELISA)检测单核细胞培养上清液肿瘤坏死因子-α(TNF-α)、白细胞介素-1β(IL-1β)的水平。结果1μmol/L阿托伐他汀减少LPS刺激下PBMC分泌TNF-α53.3%、IL-1β35.4%,10μmol/L阿托伐他汀减少TNF-α82.0%、IL-1β65.6%。结论阿托伐他汀能有效抑制LPS刺激下PBMC TNF-α及IL-1β的分泌。 Objective To observe the level of tumour necrosis factor alpha (TNF-α) and interleukin-1β (IL-1β) in human peripheral blood monocytes (PBMC) which were stimulated by LPS, and the effects of atorvastatin on it. Methods PBMCs were isolated from healthy persons by Ficoll density gradient separation and treated with atorvastatin ( 1 μmoL/L or 10 μmmol/L) for 2 hours, then LPS was added to co-culture for 1 day. TNF-α and IL-1β concentration was measured by enzyme-linked immunosorbent assay (ELISA). Result Ceils treated with 1 μmoL/L atorvastatin showed reduced TNF- α 53.3%, IL-1β 35.4%, and 10 μmoL/L reduced TNF-α 82.0%, IL-1β 65.6%. Conclusion Atorvastatin can reduce the level of TNF-α and IL-1β in human PBMC stimulated by LPS.
出处 《山东医药》 CAS 北大核心 2009年第20期10-12,共3页 Shandong Medical Journal
关键词 阿托伐他汀 外周血单核细胞 肿瘤坏死因子α 白细胞介素-1Β atorvastatin peripheral blood mononuclear cell tumour necrosis factor α interleukin-1β
  • 相关文献

参考文献8

  • 1Rider PM,Rifai N,Pfeffer MA,et al.Inflammation,pravastatin,and the risk of coronary event after myocardial infarction in patientswith average cholesterol levels:the cholesterol and recurrent events(CARE) investigatiors[J].Circulation,1998,98(9):839-844.
  • 2Holm T,Andreassen AK,Ueland T,et al.Effect of pravastatin on plasma markers of inflammation and peripheralendothelial function in male heart transplant recipients[J].Am J Cardiol,2001,87(6):815-818.
  • 3Bonetti PO,Lerman LO,Napoli C,et al.Statin effects beyond lipid lowering -are they clinically relevant[J].Eur Heart J,2003,24(3):225-248.
  • 4Libby P,Aikawa M.Effects of statins in reducing thrombotic risk and modulating plaque vulnerability[J].Clin Cardiol,2003,26(1 Suppl 1):Ⅰ11-Ⅰ14.
  • 5Van Aelst L,D'Souza-Schorey C.Rho GTPases and signaling networks[J].Genes Dev,1997,11(18):2295-2322.
  • 6Mackay DJ,Hall A.Rho GTPases[J].J Biol Chem,1998,273(33):20685-20688.
  • 7Blank N,Schiller M,Krienke S,et al.Atorvastatin inhibits T cell activation through 3-Hydroxy-3-methylglutaryl coenzyme A reductase without decreasing cholesterol synthesis[J].The Journal of Immunology,2007,179(6):3613-3621.
  • 8Wibaut-Berlaimont V,Randi AM,Mandryko V,et al.Atorvastatin affects leukocyte gene expression in dyslipidemia patients:in vivo regulation of hemostasis,inflammation and apoptosis[J].J Thromb Haemost,2005,3(4):677-685.

同被引文献13

  • 1Wakai, T., et al., Hepatitis viral status affects the pattern of intrahepatic recurrence after resection for hepatocellular carcinoma [J]. Eur J Surg Oncol, 2003, 29(3): 266-71.
  • 2Tepper RI, Mule JJ. Experimental and clinical studies ofeytokine gene2modified tumor cells[J].Hum Gene Ther, 1994,5(2): 153-164.
  • 3Pardoll DM. Paracrine cytokine adjuvants in caneerimmunotherapy. [J]. Annu Rev Immunol, 1995, 13:339-415.
  • 4Morita T, Ikeda K, Douzona M, et al. Tumor Vaccination withmacrophage colony-stimulating factor producing Lewis lungcarcinoma in mice[J]. Blood, 1996,88(3):955-961.
  • 5Ulmer, J.B., B. Wahren, and M.A. Liu, Gene-based vaccines: recent technical and clinical advances [J]. Trends Mol Med, 2006, 12(5): 216-22.
  • 6Hege, K.M., K. Jooss, and D. Pardoll, GM-CSF gene-modifed cancer cell immunotherapies: of mice and men [J]. Int Rev Immunol, 2006, 25(5-6): 321-52.
  • 7Eager, R. and J. Nemtmaitis, GM-CSF gene-transduced tumor vaccines [J]. Mol Ther, 2005,12(1): 18-27.
  • 8Soiffer, R., et al., Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colonystimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma [J]. J Clin Oncol, 2003, 21(17): 3343-50.
  • 9Simons, J.W., et al. Phase Ⅰ/Ⅱ trial of an allogeneic cellular im-munotherapy in hormone-naive prostate cancer [J]. Clin Cancer Res, 2006, 12(11 Pt 1): 3394-401.
  • 10Nemunaitis, J., et al., Phase 1/2 trial of autologous tumor mixed with an allogeneic GVAX vaccine in advanced-stage non-small-cell lung cancer[J]. Cancer G-ene Ther, 2006,13(6): p. 555-62.

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部